Get started

Biotech

Slow Churn Higher Or Another Pause For BLCM?"Since August 21st, Bellicum’s stock has made a very strong rally on the back of news releases. The price of the biotech penny stock is up nearly over 30% since the beginning of the month. This gain and volume increase came initially following the company’s $140 million public offering on the 21st. Bellicum is also participating in 3 healthcare investor conferences throughout September." Source: A List Of Penny Stocks To Watch As They Approach September Highs pennystocks.com And I understand how speculation could play a role. However, there's less volume now compared to a few weeks ago and it's approaching a level that also falls in line with previous levels it was at before.
B
by PennyStocks101
AVEO Fake Out? Or Consolidation Before Another Breakout?Aveo recently announced that the Tivozanib drug , in its second analysis, showed an improved survival hazard ratio. This penny stock news prompted the company’s stock to fly over 60% from Monday’s opening bell to Tuesday’s premarket high of $1.10. But just as quickly as it jumped, AVEO pulled back aggressively during the last 30 minutes of trading on September 10. Good Phase 3 news? Seemingly so but will profit taking crush the hopes of this breaking beyond $1 for good? Chart indicates possible technical levels and it seems that around today's high is one of those levels. "Biopharmaceutical company, Aveo Pharmaceuticals Inc. ( AVEO ) is pursuing treatment plans for different tumors. The company has 4 treatment plans in clinical trials and 2 additional ones undergoing pre-trials. Aveo’s lead product, Tivozanib, has completed the clinical trials and has been filed and marketed." Source: A List Of Penny Stocks To Watch As They Approach September Highs
A
by PennyStocks101
Bullish GartleyAbout CFMS Conformis, Inc. (NASDAQ: CFMS), is a medical device/ technology company that uses its proprietary iFit 'Image-to-Implant' technology platform to develop, manufacture and sell patient specific joint replacement implants that are designed to fit each patient's unique anatomy. Technicals Bullish Gartley pattern (786 retracement) Fibonacci confluence at the 1.272 extension 382 continuation pattern (Keeps bouncing off and making higher lows-- if it continues it could be used to further add) In-line with Fibonacci time-cycles RSI pushing higher on Daily and Weekly Potential gap up to fill up to the $2.75 level. Conclusion : CFMS has sufficient funds, great management and recently received some 510 certifications while broader markets were selling off. Looking to re-claim those prior gains. Will revisit the trade at or around time of the gap filling. Like and follow so I can continue finding awesome charts and trades. Thank you in advance d+) Twitter + Instagram @VolatilityWatch Disclosure: I am long CFMS. This is not a note to buy or sell, please do your homework before investing.
CLong
by follow_the_money
Bullish SharkLeap is looking to make another leap. Harmonic shark patterns leave more room for volatility trades and make for high reward scenario's when traded correctly. As of today (09-04-2019), 84,220 of the 261,828 shares traded where short. This is equivalent to a sizable 32.17% short percent. The technical's are now aligning with some key dates with a potential short squeeze on its way (assuming good data). $LPTX is trading at the lower end of the long-term trading range. Bullish harmonic shark pattern, look for profit taking and/ or chances to add at the 382 and 50 retracement levels to ride up to the top of the range. Not only does this trade have massive upside potential for a swing trade, it is also showing confluence with Fibonacci time-cycles, fib-retracement and trend. Tip of the day: Learning how to be disciplined is vital to trading volatility. Follow our trading team for ideas on how to stay more disciplined in biotech. Disclosure: I have no position in LPTX. I may buy or sell in the next 72 hours. This is not a note to but or sell. Please do your homework before investing.
NASDAQ:LPTXLong
by follow_the_money
Can MRNS go the distance this week?"On Tuesday, the company earned attention from analysts at H.C. Wainwright. The research firm initiated coverage on MRNS stock. It gave the company a “BUY” rating as well as a price target of $5 per share. This was the 3rd analyst firm to initiate coverage on the stock this year. Previous to H.C. Wainwright, Jefferies and Leerink Swann both initiated coverage with “BUY” and “Outperform” ratings, respectively, for the penny stock. The two other firms also..." 3 Penny Stocks Making New Highs In September NASDAQ:MRNS
M
by PennyStocks101
ABEO Stock To Watch (But For How Long?)ABEO stock has been beaten down for much of 2019. It had declined by as much as 80% since the beginning of the year. It went on to emerge as one of the biggest gainers in the market yesterday. The company announced that it was going to explore options that could unlock value for the shareholders. It stated that even an outright sale or a takeover is being considered. However, volume has been cut down dramatically on Wednesday compared to Tuesday's volume. How long can the run sustain and what will come of ABEO later this month? 3 Penny Stocks Making New Highs In September NASDAQ:ABEO
NASDAQ:ABEO
by PennyStocks101
NTEC Jumped above $0.70 since falling apartWhat are the thoughts here? News? -NOPE...pure momentum today? Biggest volume it's had since the big drop day so what can explain this move? "Intec Pharma Ltd. is a biotechnology company that creates drugs using its Accordion Pill technology. This technology is designed to improve the safety of drugs when taken orally. The company currently has 5 treatments in its pipeline with AP-CD/LD in Phase 3 trials.Over the last 2 trading sessions, Intec’s stock price has seen significant gains. On August 27th the stock price rose 14.8% and in premarket trading, on the 28th it has risen another 15%. These percentage gains allowed the biotech penny stock to go from $0.45 to $0.61." Original Article: 4 Penny Stocks To Watch Under $4 NASDAQ:NTEC
N
by PennyStocks101
Repeating Pattern #VolatilityWatchNeckline (outlined in blue) for inverse Head and shoulders. Harmonic Cypher pattern @786 retracement, where ADMA bounced. RSI moving up with trend, showing strong accumulation (Bulls in control) Highlighted in the blue box's is a pattern that I've been watching for awhile now. As you can see, they are very similar and just so happens that today's close was pushing up against the top of the neckline for the head and shoulders. Seems ADMA could have a significant move within the next few days Also, for those who aren't familiar with ADMA, they do have an announcement/PR for one of their lead products - Bivigam, to launch... Coming soon =) Please like and follow so I can continue finding awesome charts. Thank you in advance everyone d=) Disclosure: I am long ADMA. This is not a note to buy or sell, please do your homework before investing.
NASDAQ:ADMALong
by follow_the_money
$AMPE Ampio Pharmaceuticals Inc A Good Risk/Reward PlayWe are really liking the chart on $AMPE. You have the rounding bottom and there looks to be accumulation going on. Currently trading at $.62 a share, the 52-week low is $.35 a share. We believe $AMPE has breakout written all over it and there is an upcoming catalyst that can send the stock flying higher. The company is due to hear from the FDA shortly. Here's what the company said last month in its update: Ampio Pharmaceuticals has been in contact with the U.S. Food and Drug Administration (FDA) regarding the Special Protocol Assessment (SPA) following its re-submission of a revised protocol for AP-013, which the Company believes implements all of the Agency's recommendations provided since the beginning of the SPA review cycle. The Agency confirmed that it would make every effort to expedite this review, however due to a heavy workload, they were not able to commit to providing a response to the Company's SPA re-submission earlier than the 45-day window outlined in the Guidance for Industry Special Protocol Assessment, leading the Company to expect the response will be in mid-June rather than late May 2019, as previously predicted. There is some debate on social channels as to when this news will hit the tape. Some are saying any day now, while others are saying after the July 4th holiday. As always, trade with caution and use protective stops. Good luck to all!
ALong
by OptionsGains
$VIVE Viveve Medical Inc Has Gaps To Fill$VIVE has come across our screen after the company received 510k approval of its Viveve System 2.0, which is its second generation product. This is a big development and explains why the stock is up 24% today. We believe there's a lot more room for $VIVE to run as there are gaps above that need to be filled. There's $1.50 to $1.84 and then $2.50 to $3.18 Furthermore, the risk/reward looks good. Can go Long here with a stop at new 52-week lows at $.41 a share. As always, trade with caution and use protective stops. Good luck to all! About Viveve Viveve Medical, Inc. is a medical technology company focused on women's intimate health. Viveve is committed to advancing new solutions to improve women's overall well-being and quality of life. The internationally patented Viveve® System incorporates cryogen-cooled monopolar radiofrequency (CMRF) technology to uniformly deliver volumetric heating while gently cooling surface tissue to generate neocollagenesis in a single in-office session. International regulatory approvals and clearances have been received for vaginal laxity and/or improvement in sexual function indications in over 50 countries. Viveve is conducting VIVEVE II, a multicenter, randomized, double-blind, sham-controlled clinical trial to assess improvement of sexual function in women following vaginal childbirth. Completion of full 250 subject enrollment was announced in early March 2019. If successful, VIVEVE II results could support a marketing application for a new U.S. commercial indication. Currently, in the United States, the Viveve® System is cleared by the FDA for use in general surgical procedures for electrocoagulation and hemostasis. Viveve has fully enrolled LIBERATE-International, one of two planned independent, multicenter, randomized registration trials for the improvement of stress urinary incontinence in women and plans to re-submit an IDE to the FDA for LIBERATE-U.S. after conducting certain safety testing. The results of these two trials, if successful, could support marketing applications in the U.S. and over 30 countries around the world for this new commercial indication.
VLong
by OptionsGains